Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs VICI Properties Inc (VICI) Price & Performance

IDEXX Laboratories, Inc.Trade
VICI Properties IncTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs VICI Properties Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while VICI Properties Inc trades at $22.92 (market cap $25.09B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and VICI Properties Inc pays a 8.07% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and VICI Properties Inc for 43 Days on average.

IDXXVICI
Market Cap
$40.43B$25.09B
Volume
692,16417,066,337
Sector
HealthReal Estate
52-Week High
$766.68$31.42
52-Week Low
$504.70$22.53
Typical Hold Time
46 Days43 Days
Enterprise Value
$41.32B$42.65B
Dividend Yield
—8.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.

The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.

VICI Properties Inc

VICI Properties trades at $22.88, down 1.06% with a bearish technical signal despite strong fundamentals including a 67.5% net income margin and attractive valuation at 8.83 P/E. The stock shows mixed earnings performance with recent misses but maintains robust cash flow and dividend coverage. Recent news highlights tenant diversification through new leases while addressing market concerns about regional casino exposure and rising interest rates.

The investment case balances deep value metrics against sector headwinds, with analyst consensus strongly bullish ($28.90 target) but technical weakness suggesting near-term pressure. Key opportunities include the 7.8% dividend yield with 1.3x coverage, while risks center on tenant concentration and interest rate sensitivity in the REIT structure.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IDXX

No sentiment data available yet.

VICI
100% Buy0% Sell
Avg holding period · 43 Days

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →

About VICI Properties Inc

VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.

Read more on VICI →